Shots:
- Genevant to receive up to $600M up front and milestone as well as royalties on future product sales
- Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets
- The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis
Click here to read full press release/ article | Ref: Businesswire | Image: Linkedin
The post Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis first appeared on PharmaShots.
